Magnesium Acetate Tetrahydrate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Magnesium Acetate Tetrahydrate
- Magnesium Acetate Tetrahydrate: From Parenteral Nutrition Component to Migraine Disorder
Magnesium Acetate Tetrahydrate: From Parenteral Nutrition Component to Migraine Disorder
One-Sentence Summary
Magnesium acetate tetrahydrate is an electrolyte component of parenteral nutrition emulsions (Nutriflex Omega products) marketed in Singapore. The TxGNN model predicts it may be effective for migraine disorder, but no clinical trials and no publications were found in the data compiled for this report. The prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the Singapore registration data (indication text is blank for all licences) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 95.28% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, magnesium acetate tetrahydrate is a magnesium salt used as an electrolyte source in intravenous nutrition emulsions, where it supplies magnesium to patients who cannot take nutrition orally. Its use there is to replace a nutrient, not to treat a specific disease.
Magnesium is biologically plausible for migraine. It modulates NMDA receptors and cortical spreading depression, and it influences serotonin signalling and vascular tone. This is general background knowledge and is not supported by any trial or publication in the data compiled for this report. There is also no migraine-specific evidence for the acetate salt itself. The prediction should therefore be treated as a hypothesis for further research, not as a finding.
Other predictions follow the same pattern. Migraine with brainstem aura, headache disorder and trigeminal autonomic cephalalgia (scores 91.5–94.5%) likely reflect the parent migraine association. The glaucoma predictions (open-angle and primary hereditary, about 92%) have only a hypothetical vascular or neuroprotective link. The rare skin disorders and nephrogenic syndrome of inappropriate antidiuresis (scores 84.8–87.9%) have no apparent mechanistic connection and look like knowledge-graph artefacts.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16734P | Nutriflex Omega Special B. Braun Emulsion for Infusion | Injection, emulsion | Not stated |
| SIN15468P | Nutriflex Omega Plus Emulsion for Infusion | Injection, emulsion | Not stated |
| SIN15469P | Nutriflex Omega Special Emulsion for Infusion | Injection, emulsion | Not stated |
All three are valid single-ingredient registrations held by B. Braun Melsungen AG, and all are injectable.
Safety Considerations
Please refer to the package insert for safety information. No warnings, contraindications or drug interaction records were available in the data compiled for this report. Magnesium is cleared by the kidneys, so renal function is a general consideration for any magnesium-containing product.
Conclusion and Next Steps
Decision: Hold
Rationale: The migraine prediction has a high model score (95.3%) and a plausible biological story. However, there are no clinical trials or publications in the data compiled for this report, and the evidence level is L5 (model prediction only). Safety information is also missing, so the case cannot advance to safety screening.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website
- Mechanism of action data for the compound
- A literature and trial search on magnesium (including other salts) for migraine, to see whether existing evidence transfers to the acetate salt
- Confirmation of the approved indications for the three Nutriflex Omega registrations
- Route compatibility assessment: the registered products are intravenous nutrition emulsions, and the route and formulation suited to migraine use have not been assessed
- Subtype-specific data before any action on migraine with brainstem aura, headache disorder or the other lower-ranked predictions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.